BreakingNews

Category archive

Health

New Atlanta Addiction Recovery Center

Reading Time: 2 minutes

New Atlanta Addiction Recovery Center Combines Evidence-Based Addiction Treatment with Christian Rehab

ATLANTA, June 19, 2017 /360WiseNews/ — RiverMend Health, a premier provider of scientifically-driven behavioral health services for those suffering from alcohol and drug addiction, has announced the launch of a new Christian addiction treatment center in Atlanta.

RiverMend Health’s new Atlanta-based Addiction Recovery Center Ribbon Cutting Front row, left to right: Ashley Buffington, LPC, MS - Lead Therapist; Angela Dainas, M.Ed, LMFT – Therapist; Catherine Baer, MS, MS, LPC – Clinical Director; Daniel Lettenberger-Klein, MS, LMFT – Executive Director; Edmund Bujalski – CEO; Stacy Seikel, MD – Medical Director

Atlanta Addiction Recovery Center (AARC) provides a spiritually nourishing environment with the highest level of medical, clinical and psychiatric care for adults struggling with addiction and dual disorders such as depression, anxiety and post-traumatic stress. This treatment process creates a lasting foundation for recovery, while enabling patients to draw strength from their Christian faith.

Keep Reading

Veterans Empowered at Project Fitness in Atlanta GA

Health/Military by
Reading Time: 2 minutes

Veterans Empowered at Wounded Warrior Project Fitness Program in Atlanta

ATLANTA, June 19, 2017 /360WiseNews/ — Life Time Athletic recently opened its doors to injured veterans taking part in a Wounded Warrior Project® (WWP) Physical Health and Wellness coaching program in Atlanta. As they spent three days exploring exercise, nutrition, and lifestyle goals, warriors reaped the benefits of getting out of the house and connecting with fellow service members.

Keep Reading

BREAKING: Drugs of Abuse Testing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024

Reading Time: 3 minutes

NEW YORK, April 6, 2017 /360WiseNews/ — Global Drugs of Abuse Testing Market: Scope and Methodology

This report on the global drugs of abuse testing market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

Read the full report: http://www.reportlinker.com/p04589986/Drugs-of-Abuse-Testing-Market-Global-Industry-Analysis-Size-Share-Growth-Trends-and-Forecast.html

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2015 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global drugs of abuse testing market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global drugs of abuse testing market. Keep Reading

Family Fights to Stop Hewlett Packard and Insurer From Cutting Off Healthcare that Saves Father’s Life, According to Federal Lawsuit by Jonathan Davidson Law Firm

Reading Time: 2 minutes

RIVERSIDE, Calif., March 30, 2017 /360WiseNews/ — According to a lawsuit filed in the federal District Court in the Northern District of California in San Jose, the experience of one patient, Jonathan Davidson, puts a spotlight on the large companies Hewlett Packard Enterprise and United HealthCare seeking to manipulate healthcare payment systems by cutting off a patient’s life-saving care, as alleged in the lawsuit in which Mr. Davidson’s Jonathan Davidson Law Firm is representing him. Hewlett Packard Enterprise (HP) plans a merger this week with another giant computer services company, Computer Sciences Corporation, which has repeatedly been charged with systematically engaging in false or fraudulent practices in its business with Medicaid, the British National Health Service and others. In the merger, 120,000 or so HP employees are set to be “spun off” into a newly created HP-CSC merger company called “DXC Technology,” with their prior HP sponsored health plan replaced by a “private exchange model” adopted for its “lower cost structure” for HP.

According to Jonathan Davidson, his case exemplifies the abuses that victimize millions of ill patients, including employees and others with company or group medical coverage, and also the public and taxpayers through inflated medical and health insurance costs. Keep Reading

Global Breast Cancer Therapeutics Market Analysis 2016-2022: Company Profiling Covering the Financials, Recent Activities and Future Strategies – Research and Markets

Reading Time: 2 minutes

DUBLIN, Mar 01, 2017 /360WiseNews/ —

Research and Markets has announced the addition of the “Global Breast Cancer Therapeutics Market Analysis 2016 – Forecast to 2022” report to their offering.

Research and Markets Logo

The market overview offers in depth analysis at the regional and country level, for instance North America (U.S., Canada and Mexico), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, Australia, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America).

Annual estimations and forecasts are provided from the year 2013 to 2022 for each given segment and sub segments. Market data derived from the authenticated and reliable sources is subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends.

Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, and other activities.

This report provides:

– Market Sizing estimations and forecasts for 6 years across the given market segments
– Identifying market dynamics (Drivers, Restraints, Opportunities, Threats, Challenges and Opportunities, )
– Strategic recommendations in key business segments based on the market estimations
– Regional and country level market analysis
– Competitive landscaping of major market players
– Company profiling covering the financials, recent activities and the future strategies

Key Topics Covered:

1 Introduction
1.1 Scope of the Report
1.2 Report Description
1.3 Research Methodology
1.4 Research Sources
1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Assumptions
1.5 List of Abbreviations

2 Executive Summary

3 Market Analysis
3.1 Market Segmentation
3.2 Market Size Estimation
3.3 Market Drivers
3.4 Market Constraints

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Breast Cancer Therapeutics Market by Clinical Study
5.1 Introduction
5.2 Phase I
5.3 Phase II
5.4 Phase III Drugs

6 Breast Cancer Therapeutics Market by Drug Class
6.1 Introduction
6.2 Mitotic Inhibitors
6.2.1 Ixempra (Ixabepilone)
6.2.2 Halaven (Eribulin)
6.2.3 Taxotere (Docetaxel)
6.3 Anti-metabolites
6.3.1 Gemzar (Gemcitabine)
6.4 Hormone Receptor
6.4.1 Zoladex
6.4.2 Faslodex
6.4.3 Fareston
6.5 Aromatase Inhibitors
6.5.1 Femara (Leterozole)
6.5.2 Arimidex (Anastrozole)
6.5.3 Aromasin (Exemestane)
6.5.4 Ibrance (Palbociclib)
6.5.5 Afinitor (Everolimus)
6.6 HER2 Inhibitors
6.6.1 Kadcyla (Ado-trastuzumab emtansine)
6.6.2 Tykerb (Lapatinib)
6.6.3 Perjeta (Pertuzumab)
6.6.4 Herceptin (Trastuzumab) Keep Reading

Sleep Apnea Global Clinical Trials Review, H2, 2016

Health by
Reading Time: 2 minutes

NEW YORK, Feb. 15, 2017 /360WiseNews/ — Sleep Apnea Global Clinical Trials Review, H2, 2016

Summary

GlobalData’s clinical trial report, “Sleep Apnea Global Clinical Trials Review, H2, 2016” provides an overview of Sleep Apnea clinical trials scenario. This report provides top line data relating to the clinical trials on Sleep Apnea. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Keep Reading

Premature Birth Is Linked To Mom’s Heart Disease Later In Life

Health by
Reading Time: 2 minutes

March of Dimes Believes More Research Urgently Needed

WHITE PLAINS, N.Y., Feb. 3, 2017 /PRNewswire-USNewswire/ 360WiseNews/ — Having a premature baby raises a woman’s risk for heart attack or stroke later in life, according to a study published February 2 in Circulation at the start of American Heart Month.

Lauren J. Tanz, MSPH, and colleagues at the Harvard T.H. Chan School of Public Health analyzed data from more than 70,000 participants in the ongoing Nurses’ Health Study II at Harvard to examine the association between premature delivery and future cardiovascular disease (CVD). They found that women who delivered a baby before 37 weeks gestation in their first birth had a 40 percent greater risk of heart disease later in life, even after accounting for pre-pregnancy sociodemographic, lifestyle, and CVD risk factors, compared to women with term deliveries.

Women who delivered before 32 weeks gestation had double the risk of CVD compared to women with term deliveries.

The researchers say premature delivery may be an early warning sign of future heart problems, rather than the cause of them. More research is needed to determine the pathways through which premature delivery and CVD are linked.  Keep Reading

Go to Top